Danaher Corporation
Danaher Corporation Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
What the Q2 FY26 call signalled
2 of 4 strong
The short version
- Full-year 2026 core revenue growth guidance remains at 3% to 6%, with low single-digit growth expected in Q2 and acceleration through the year. - Danaher expects mid- to high single-digit earnings growth in H1 2026, putting them on track for the full year.
From Danaher Corporation's Q2 FY26 earnings-call transcript · updated 29 May 2026.
Revenue & Sales Performance
- Full-year 2026 core revenue growth guidance remains at 3% to 6%, with low single-digit growth expected in Q2 and acceleration through the year.
- Headwinds from China diagnostics, respiratory, and life sciences comps (~300 basis points) are expected to abate by year-end, enabling mid-single-digit core growth exit in Q4.
- Encouraged by early 2026 momentum: Life Sciences and Biotechnology businesses in China accelerating; bioprocessing consumables showing consistent high single-digit growth; equipment orders improving with over 30% YoY increase.
- Equipment orders growth in bioprocessing expected to support growth beyond 2026, though 2026 guide assumes flat equipment revenue.
2 more points from Danaher Corporation's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Danaher Corporation said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Danaher is accelerating growth investments, moving some from the second half of the year into Q2 to capitalize on opportunities.
- There is notable investment activity in bioprocessing equipment, supported by more than 30% year-over-year order growth, driven by underinvestment in capacity and new biosimilars and compounds entering the market.
- Brownfield and greenfield investments are underway, including equipment capacity expansions and reshoring-related projects, with some orders already placed for brownfield expansions.
- The company is enhancing its portfolio via strategic M&A, highlighted by the pending acquisition of Masimo, expected to close later this year.
2 more points from Danaher Corporation's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Danaher Corporation said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Bioprocessing equipment orders showed over 30% year-over-year growth in Q1, coming off a lower base the previous year.
- The first quarter orders growth was the first positive year-over-year growth in nearly 2 years.
- Sequentially, Q1 orders were slightly down quarter-over-quarter due to typical seasonality.
- Equipment order book trends are supported by robust funnel activity and larger order sizes.
- Orders growth driven by two factors: underinvestment in capacity (brownfield and greenfield investments) and reshoring dynamics.
- Equipment orders assumed to be flat for the full year 2026, with positive indicators for future growth beyond 2026.
- Customer readiness may cause lumpiness in equipment revenue recognition.
2 more points from Danaher Corporation's call on order book
Create a free account to keep reading this call
Continue your research
Others in Life Sciences Tools and Services this season
- Revvity, Inc. (Q2 FY26)
Revvity, Inc. Q2 FY26 quarterly results analysis. 2026 revenue guidance updated to $2.81 billion - $2.84 billion, with pro forma organic growth expected at 3% t
- Medpace Holdings, Inc. (Q2 FY26)
Medpace Holdings, Inc. Q2 FY26 quarterly results analysis. Revenue is expected to remain within the current guidance range for 2026 despite higher cancellations
- Illumina, Inc. (Q2 FY26)
Illumina, Inc. Q2 FY26 quarterly results analysis. Illumina expects continued strong momentum in clinical sales, projecting mid-teens growth for the clinical ma
- Mettler-Toledo International Inc. (Q2 FY26)
Mettler-Toledo International Inc. Q2 FY26 quarterly results analysis. The company expects local currency sales growth of approximately 4% for full year 2026, in
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Danaher Corporation and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Danaher Corporation Q2 FY26 results?
- Full-year 2026 core revenue growth guidance remains at 3% to 6%, with low single-digit growth expected in Q2 and acceleration through the year. - Danaher expects mid- to high single-digit earnings growth in H1 2026, putting them on track for the full year.
What is Danaher Corporation share price analysis?
Danaher Corporation currently shows a neutral. The stock trades at a P/E of 33.5 with a market cap of $127,845. Investors should review the full earnings analysis for detailed insights.
Is Danaher Corporation planning capital expenditure?
- Danaher is accelerating growth investments, moving some from the second half of the year into Q2 to capitalize on opportunities.
Keep Danaher Corporation on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.